A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics,
and efficacy of SHR-A1811 for injection in subjects with advanced non-small cell lung cancer
who have HER2 expression , amplification, or mutation